ArticleJournal of cellular and molecular medicine2026
Inhibited Differentiation and Growth of Myocyte Associated With Sarcopenia: The Key Role of the lncRNA A430093F15Rik/microRNA-337-3p/Fam168a Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sarcopenia is a muscle disorder characterized by progressive loss of muscle mass, strength and function with ageing. Non-coding RNAs have been reported to be involved in the progression of sarcopenia. The current study aimed to investigate the pathogenesis of sarcopenia. Based on the bioinformatics analyses and RT-qPCR validation, the lncRNA A430093F15Rik was selected as the potential target involved in sarcopenia progression. Its expression level was up-regulated with ageing in mice but down-regulated with myogenesis in C2C12 cells. Modulating A430093F15Rik showed that the inhibition of the lncRNA contributed to the attenuation of sarcopenia such as increased cell viability and enhanced myogenesis, while the overexpression promoted disease progression. The downstream effector of A430093F15Rik, miR-337-3p, showed opposite function to the lncRNA, while Fam168a showed similar effects. Moreover, modulating both factors also confirmed their distinct roles during sarcopenia progression. The dual luciferase and RNA pulldown assays then verified the direct binding between A430093F15Rik and miR-337-3p, and miR-337-3p and Fam168a, representing a ceRNA regulatory mechanism between A430093F15Rik, miR-337-3p and Fam168a. The current study identified a novel lncRNA, A430093F15Rik, that is involved in the progression of sarcopenia by acting as a competitive endogenous RNA (ceRNA) to sponge miR-337-3p and regulate the expression of Fam168a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.